Video • LIMA project

Agena Bioscience’s liquid biopsy technology awarded Horizon 2020 grant

Agena Bioscience, a global provider of molecular genetic solutions, announced it has been selected to participate as an innovative technology provider in the ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA) project.

The LIMA project has been awarded a EUR 6.3 million Horizon 2020 European Union research grant to develop an integrated approach for personalized cancer treatment. The objective of the four-year project is to develop and validate liquid biopsy technologies in the clinical workflow and to provide more precise, dynamic tumor characterization during diagnosis and treatment. Agena Bioscience’s MassARRAY System will be used to provide molecular genetic information from liquid biopsies. In collaboration, advanced Magnetic Resonance Imaging (MRI) from Royal Philips will be utilized for in-vivo tumor characterization.

Liquid biopsy is an emerging field of oncology diagnostics where disease prognostic and resistance markers are identified from circulating tumor DNA and cells present in blood. Liquid biopsies are non-invasive, provide a more accurate picture of the disease’s heterogeneity, and are repeatable at regular intervals to monitor the diseases’ status and response to treatment.

We are excited to participate in the LIMA project as a subject matter expert for the characterization of liquid biopsies

David Coorey

The UltraSEEK chemistry on the MassARRAY System enables detection of over 50 variants from a single blood draw, as low as 0.1% variant allele frequency. The simple workflow generates results in as fast as a day, enabling minimal residual disease and resistance monitoring.

“We are excited to participate in the LIMA project as a subject matter expert for the characterization of liquid biopsies,” commented David Coorey, Vice President & Managing Director, EMEA at Agena Bioscience. “The MassARRAY System’s low limit of detection along with advanced MRIs could provide better genotypic and phenotypic characterization of the disease, helping physicians make more informed personalized treatment decisions, thereby improving patient care.”

The MassARRAY Dx is CE-IVD marked for use in Europe Only. The MassARRAY System and UltraSEEK are for Research Use Only. Not for use in diagnostic procedures.


Source: Agena Bioscience

01.12.2017

Related articles

Photo

Article • Transformative technology

Generative AI in healthcare: More than a chatbot

‘Computer, why did the doctor take that MRI scan of my leg? And what did it show?’: Popularized by OpenAI’s ChatGPT, generative artificial intelligence (AI) is already beginning to see…

Photo

Article • Oncology imaging

The expanding role of CT in lung cancer management

While screening programs for several of the commonest cancers are now well established, lung cancer screening has yet to reach anywhere near the same proportion of at-risk patients.

Photo

Article • Philips presents portfolio update at ECR 2022

AI-powered MRI to increase imaging speed, reduce staff burden

The portfolio Philips presented at ECR 2022 revealed that the company not only advanced their products, but also listened to medical professionals and patients – and took their feedback to heart.

Related products

Subscribe to Newsletter